Uncategorized-EN
Should I join a clinical trial?
When you have been diagnosed with sarcoma you are faced with making important, and at times daunting decisions about treatment. Amongst the treatment choices, a clinical trial may be an option. But how do you know if it is a good option for you? Is it something you should even consider? Denise Reinke asks 6 key questions about clinical trials and provides helpful answers for sarcoma patients to consider.
Read MoreINSIGHT: Ripretinib vs Sunitinib in advanced GIST with specific KIT Exon mutations
Trial name: INSIGHT Agents: Ripretinib vs. Sunitinib Phase III Status Recruiting Sponsor Deciphera Pharmaceuticals This is a Phase 3 study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14…
Read MoreNo Losers Here!
War metaphors are used all the time in the context of cancer. “You’re a fighter! You got this!”, people say to a newly diagnosed patient.
And the war metaphors seem to imply that if someone succumbs to cancer, it’s because they didn’t fight hard enough, or worse, gave up – “He lost his battle against cancer.” Many point out that such expectations are an additional burden placed upon a person who is already undergoing so much. But I wonder: Can the use of war metaphors be of help to us sarcoma patients as we strive to take an active role in our treatment?
 Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors. Agents: BAY2757556 (Larotrectinib, Vitrakvi) Phase II Status Recruiting Sponsor Bayer For further information please also consult ClinicalTrials.gov. This is a Phase II study to test how well different types of cancer respond to the drug…
Read MoreLurbinectedin + doxorubicin as first-line treatment in metastatic leiomyosarcoma (SaLuDo)
Lurbinectedin + Doxorubicin vs. Doxorubicin alone as first-line treatment in metastatic leiomyosarcomas Agents: Lurbinectedin & Doxorubicin Phase IIb / III Status Recruiting Sponsor PharmaMar For further information please also consult ClinicalTrials.gov. This IIb/III study evaluates whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free…
Read MoreUSA: The Desmoid Tumour Research Foundation (DTRF)
USA: The Desmoid Tumour Research Foundation (DTRF) Back to members Organisation Profile The Desmoid Tumor Research Foundation (DTRF) was founded in September, 2005. Mission The Desmoid Tumor Research Foundation (DTRF) seeks to advance the science related to desmoid tumors Funding research related to the diagnosis and treatment of desmoid tumors; Facilitating and enhancing the dialogue among…
Read MoreReflections for the New Year
2023 was a big year for SPAGN and the sarcoma patient community as a whole. We look back on the highlights of all that we achieved together and the many ways in which we grew, as we look to the year ahead.
Read MoreUSA: Rein in Sarcoma
USA: Rein in Sarcoma Back to members Organization profile:Â Rein in Sarcoma is a resource for patients and families touched by sarcomas. We are a nationally-known sarcoma foundation and provide support to patients and loved ones all across the world. Founded in Minnesota in 2001, we have funded over $2 million in innovative, collaborative…
Read MoreInsights from the EMA and EORTC Workshop on Developing Treatments for Ultra-Rare Sarcomas
Author: Gerry Feeney How can we develop new treatments in ultra-rare sarcomas, as a model for ultra-rare tumors? On January 12, 2024, a workshop between regulators, researchers and patient advocates was held at the European Medicines Agency (EMA) premises in Amsterdam. The objective for the workshop was to discuss strategies to be more flexible…
Read MoreSpain: ASARGA – Association of Sarcomas Assistance Groups
Spain: ASARGA – Association of Sarcomas Assistance Groups Back to members Organisation profile ASARGA, is a nonprofit association that brings together affected all types of sarcoma in Spain, giving support to both people suffering from this disease and their families. ASARGA works in coordination with other associations at a national level that, in one way…
Read More